The estimated Net Worth of Yvonne Greenstreet is at least $35.8 Million dollars as of 20 August 2024. Yvonne Greenstreet owns over 15,000 units of Alnylam Pharmaceuticals Inc stock worth over $23,163,582 and over the last 11 years he sold ALNY stock worth over $9,405,744. In addition, he makes $3,250,030 as President and Chief Operating Officer at Alnylam Pharmaceuticals Inc.
Yvonne has made over 17 trades of the Alnylam Pharmaceuticals Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 15,000 units of ALNY stock worth $1,275,000 on 20 August 2024.
The largest trade he's ever made was exercising 57,811 units of Alnylam Pharmaceuticals Inc stock on 5 May 2020 worth over $4,184,938. On average, Yvonne trades about 3,542 units every 30 days since 2014. As of 20 August 2024 he still owns at least 88,441 units of Alnylam Pharmaceuticals Inc stock.
You can see the complete history of Yvonne Greenstreet stock trades at the bottom of the page.
Dr. Yvonne L. Greenstreet has been appointed as President, Chief Operating Officer of the Company effective 10/1/2020. She has served as the Company’s Chief Operating Officer since September 2016. Prior to joining the Company, Dr. Greenstreet most recently served as the founder and Managing Director of Highgate LLC, from January 2014 to August 2016. Prior to that time, Dr. Greenstreet served as the Senior Vice President and Head of Medicines Development at Pfizer Inc., a multinational pharmaceutical company, from December 2010 to November 2013. Prior to joining Pfizer, Dr. Greenstreet worked for 18 years at GlaxoSmithKline plc, or GSK, a multinational pharmaceutical, biologics, vaccines and consumer healthcare company, where she served in various positions, most recently as Senior Vice President and Chief of Strategy for Research and Development and as a member of GSK’s Product Management Board. Dr. Greenstreet currently serves on the Scientific Advisory Committee of the Bill and Melinda Gates Foundation and serves as a director of Pacira Pharmaceuticals and American Funds.
As the President and Chief Operating Officer of Alnylam Pharmaceuticals Inc, the total compensation of Yvonne Greenstreet at Alnylam Pharmaceuticals Inc is $3,250,030. There are 3 executives at Alnylam Pharmaceuticals Inc getting paid more, with John Maraganore having the highest compensation of $7,317,860.
Yvonne Greenstreet is 57, he's been the President and Chief Operating Officer of Alnylam Pharmaceuticals Inc since 2020. There are 15 older and 2 younger executives at Alnylam Pharmaceuticals Inc. The oldest executive at Alnylam Pharmaceuticals Inc is Phillip Sharp, 75, who is the Independent Director.
Yvonne's mailing address filed with the SEC is 675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, 02142.
Over the last 20 years, insiders at Alnylam Pharmaceuticals Inc have traded over $140,068,015 worth of Alnylam Pharmaceuticals Inc stock and bought 4,419,116 units worth $1,983,132,563 . The most active insiders traders include Sanofi, Christoph H Westphal, and Kevin P Starr. On average, Alnylam Pharmaceuticals Inc executives and independent directors trade stock every 23 days with the average trade being worth of $11,181,724. The most recent stock trade was executed by Yvonne Greenstreet on 20 August 2024, trading 15,000 units of ALNY stock currently worth $1,275,000.
alnylam is developing an entirely new class of innovative medicines based on a breakthrough discovery in biology known as rna interference, or rnai. with rnai technology, we have the opportunity to treat disease and impact the lives of patients in a fundamentally new way by silencing disease-causing genes upstream of today's medicines.
Alnylam Pharmaceuticals Inc executives and other stock owners filed with the SEC include: